2020 Neuromyelitis Optica (Devic’s Syndrome) Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs

The 2020 Neuromyelitis Optica (Devic’s Syndrome) pipeline report presents a comprehensive overview of the research and development of Neuromyelitis Optica (Devic’s Syndrome) drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: Three drugs in Research phase, Ten drugs in pre-clinical phase, six drugs in Phase 1, one drug in Phase 2, four drugs in Phase 3 and one drug pre-registration

As of February 2020, the Neuromyelitis Optica (Devic’s Syndrome) pipeline remains robust with 26 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Neuromyelitis Optica (Devic’s Syndrome) treatment. Diverse types of targeted therapies are being explored through clinical trials including Anti-FcRn fully human monoclonal antibody; B lymphocyte stimulator inhibitor; CD19 antigen inhibitors; CD20 antigen inhibitors; Complement C3 inhibitor; Complement C5 inhibitors; Cytotoxic T lymphocyte stimulants; Estrogen receptor agonists; Interleukin 6 receptor antagonists; Monoacylglycerol lipase inhibitors; NF-kappa B inhibitors; RGMA protein inhibitors; Serum-glucocorticoid regulated kinase stimulants; STAT3 transcription factor inhibitors; Steroid receptor agonists; T lymphocyte stimulants; Th17 cell modulators; RORgt antagonist.

The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Neuromyelitis Optica (Devic’s Syndrome) drug development history, latest news, and other developments.

It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.

Publisher Expertise
Our online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.

Scope:
• The report scope comprises of both pre-clinical phase and clinical phase development drugs for Neuromyelitis Optica (Devic’s Syndrome) development
• Neuromyelitis Optica (Devic’s Syndrome) pipeline compounds and molecules under study by both large scale and small companies are included in the report
• Neuromyelitis Optica (Devic’s Syndrome) pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
• Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
• Further, orphan drug status, fast track designation, different grants awarded and special status for Neuromyelitis Optica (Devic’s Syndrome) pipeline candidates included
• Business overview and snapshot of all companies involved in Neuromyelitis Optica (Devic’s Syndrome) pipeline are included
• Latest market and pipeline developments are provided in the report

Neuromyelitis Optica (Devic’s Syndrome) pipeline companies included in the report are- Accendatech Au Pty Ltd, Ahead Therapeutics SL, Alexion Pharmaceuticals Inc, Biogen Inc, Bionure Farma SL, Bio-Thera Solutions Ltd, Boston Pharmaceuticals Inc, Chord Therapeutics Sarl, Chugai Pharmaceutical Co Ltd, Cour Pharmaceuticals Development Co Inc, Endece LLC, EnhanX Biopharm Inc, Ferring International Center SA, H. Lundbeck AS, HanAll Biopharma Co Ltd, ImCyse SA, Imstem Biotechnology Inc, Mitsubishi Tanabe Pharma Corp, NovelMed Therapeutics Inc, Orion BioScience Inc, TG Therapeutics Inc, Tolerion Inc, Viela Bio Inc, Yantai RC-Pharmaceutical Co Ltd

Neuromyelitis Optica (Devic’s Syndrome) pipeline drugs profiled in the report include- ACT001, AT-1511, eculizumab, ravulizumab, rituximab, BN201, BAT4406F, ARN-6039 (BOS-172767), cladribine, SA237 (satralizumab), CNP-Aquaporin 4, NDC-1308, ENX-201 (glutathione PEGylated liposomal methylprednisolone/2B3-201), olamkicept (FE-301), ABX-1431, batoclimab, Synthetic Peptide for Neuromyelitis Optica, IMS001, IMS002, ublituximab, MT-3921, Complement C3-C5 inhibitors for Neuromyelitis Optica, ORNx-KI, TOL-3052, inebilizumab, telitacicept